Myosin: a highly sensitive indicator of myocardial necrosis after cardiac operations.
Plasma levels of ventricular myosin fragments, determined with monoclonal antibodies to myosin heavy chains, were studied in 27 patients after cardiac operations (17 aorta-coronary bypass grafts and 10 valve replacements) to assess their possible role as a marker of perioperative myocardial necrosis. Five patients had perioperative myocardial necrosis after aorta-coronary bypass grafts as indicated by changes in the electrocardiogram and elevated levels of the MB isoenzyme of creatine kinase. Six more patients were also studied after thoracic operations performed by the same sternotomy approach. After cardiac operations, myosin levels increased from postoperative day 3 and reached peak values on day 7. Peak myosin values in patients with perioperative myocardial necrosis after aorta-coronary bypass grafting were significantly higher than in patients after an identical operation but without perioperative myocardial infarction (3793 +/- 592 versus 369 +/- 47 ng/ml; p less than 0.001). These results suggest that plasma myosin is a sensitive marker of myocardial necrosis. Furthermore, peak plasma levels of ventricular myosin after coronary bypass grafting without myocardial infarction (mean value 369 +/- 47 ng/ml) were not significantly different from peak levels after thoracic operations (mean value 253 +/- 52 ng/ml), whereas they were significantly higher after valve replacement (mean value 794 +/- 149 ng/ml; p less than 0.01). These results indicate that a certain degree of myocardial necrosis occurs during value replacement that is undetectable by the usual diagnostic criteria for perioperative myocardial infarction. We conclude that the plasma level of ventricular myosin fragments is a more specific and accurate marker of perioperative myocardial necrosis than changes in the electrocardiogram or elevated creatine kinase MB levels. Therefore the detection of myosin fragments, which appear in the serum on the third day after cardiac operations, may be useful for precise comparisons of different techniques of myocardial protection.
Séguin
J R
JR
Thoracic and Cardiovascular Surgery, C.H.U. Hôpital Saint Eloi, Montpellier, France.
Saussine
M
M
Ferrière
M
M
Léger
J J
JJ
Léger
J
J
Larue
C
C
Calzolari
C
C
Grolleau
R
R
Chaptal
P A
PA
D015415:Biomarkers / Q000097:blood; D001026:Coronary Artery Bypass; D006349:Heart Valve Diseases / Q000601:surgery*; D006801:Humans; D009203:Myocardial Infarction / Q000097:blood* / Q000473:pathology; D009218:Myosins / Q000097:blood*; D009336:Necrosis; D011183:Postoperative Complications / Q000097:blood*
D015415:Biomarkers; D009218:Myosins